agarthancha
Sphinx
- Joined
- Feb 15, 2026
- Posts
- 2,872
- Reputation
- 2,396
Back up your claims. Also it lacks in effectivness and is overly expensive
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study - PubMed
FGFR inhibitor monotherapy with infigratinib had limited efficacy in a population of patients with recurrent gliomas and different FGFR genetic alterations, but durable disease control lasting more than 1 year was observed in patients with tumors harboring FGFR1 or FGFR3 point mutations or...
.That’s about all I’m running. As for an fgfr3 inhibitor I’ve found a few tele accounts and other research chem sites that supposedly sell them but I have not ordered yet.